enGene (ENGN) Competitors $5.18 +0.18 (+3.60%) Closing price 04:00 PM EasternExtended Trading$5.18 +0.00 (+0.10%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. QURE, SANA, AKBA, PHAT, AMLX, AVXL, TSHA, AVBP, NAGE, and GYREShould you be buying enGene stock or one of its competitors? The main competitors of enGene include uniQure (QURE), Sana Biotechnology (SANA), Akebia Therapeutics (AKBA), Phathom Pharmaceuticals (PHAT), Amylyx Pharmaceuticals (AMLX), Anavex Life Sciences (AVXL), Taysha Gene Therapies (TSHA), ArriVent BioPharma (AVBP), Niagen Bioscience (NAGE), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. enGene vs. Its Competitors uniQure Sana Biotechnology Akebia Therapeutics Phathom Pharmaceuticals Amylyx Pharmaceuticals Anavex Life Sciences Taysha Gene Therapies ArriVent BioPharma Niagen Bioscience Gyre Therapeutics enGene (NASDAQ:ENGN) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings. Do insiders and institutionals have more ownership in ENGN or QURE? 64.2% of enGene shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 10.4% of enGene shares are held by insiders. Comparatively, 4.8% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media refer more to ENGN or QURE? In the previous week, enGene had 10 more articles in the media than uniQure. MarketBeat recorded 13 mentions for enGene and 3 mentions for uniQure. uniQure's average media sentiment score of 0.00 beat enGene's score of -0.19 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral uniQure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, ENGN or QURE? enGene has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.65-3.14uniQure$27.12M36.39-$239.56M-$3.92-4.59 Which has more volatility & risk, ENGN or QURE? enGene has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, uniQure has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Do analysts rate ENGN or QURE? enGene presently has a consensus target price of $23.29, indicating a potential upside of 349.79%. uniQure has a consensus target price of $37.45, indicating a potential upside of 108.23%. Given enGene's higher possible upside, research analysts clearly believe enGene is more favorable than uniQure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00uniQure 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is ENGN or QURE more profitable? enGene has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. enGene's return on equity of -32.60% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -32.60% -28.26% uniQure -1,387.98%-1,010.74%-33.27% SummaryenGene beats uniQure on 9 of the 15 factors compared between the two stocks. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$264.55M$3.16B$5.78B$9.92BDividend YieldN/A2.28%6.67%4.52%P/E Ratio-3.1421.1175.6726.67Price / SalesN/A463.83554.40206.13Price / CashN/A45.1137.1158.92Price / Book0.979.8611.446.09Net Income-$55.14M-$53.47M$3.28B$266.14M7 Day Performance12.06%2.79%0.78%0.22%1 Month Performance31.40%8.49%7.07%4.08%1 Year Performance-20.72%13.61%59.61%23.89% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene3.1726 of 5 stars$5.18+3.6%$23.29+349.5%-24.4%$264.70MN/A-3.1431Upcoming EarningsShort Interest ↓QUREuniQure1.9246 of 5 stars$15.55-1.0%$37.45+140.9%+227.7%$861.41M$27.12M-3.97500News CoverageAnalyst ForecastSANASana Biotechnology2.6957 of 5 stars$3.35-6.4%$8.00+138.8%-45.8%$851.35MN/A-3.16380News CoveragePositive NewsAKBAAkebia Therapeutics3.8181 of 5 stars$3.03-5.0%$6.75+122.8%+116.5%$845.81M$160.18M-17.82430PHATPhathom Pharmaceuticals3.0916 of 5 stars$11.57-2.9%$17.50+51.3%-29.4%$844.94M$114.04M-2.45110Positive NewsAMLXAmylyx Pharmaceuticals2.5993 of 5 stars$8.50-8.6%$11.75+38.2%+376.1%$829.26M$87.37M-3.40200News CoveragePositive NewsAVXLAnavex Life Sciences3.9612 of 5 stars$9.40-1.4%$44.00+368.1%+66.5%$818.57MN/A-16.4940Positive NewsTSHATaysha Gene Therapies2.0078 of 5 stars$2.92-2.7%$8.29+183.8%+57.5%$818.39M$8.10M-8.59180News CoveragePositive NewsAVBPArriVent BioPharma2.517 of 5 stars$19.35-3.8%$39.14+102.3%-25.3%$815.84MN/A-4.8140Positive NewsNAGENiagen Bioscience2.3018 of 5 stars$10.03+0.5%$13.42+33.8%N/A$795.93M$99.60M47.76120GYREGyre Therapeutics1.5677 of 5 stars$8.20+0.2%N/A-38.7%$787.84M$105.76M820.8240High Trading Volume Related Companies and Tools Related Companies QURE Competitors SANA Competitors AKBA Competitors PHAT Competitors AMLX Competitors AVXL Competitors TSHA Competitors AVBP Competitors NAGE Competitors GYRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
